Diabetic peripheral neuropathy: advances in diagnosis and strategies for screening and early intervention
dc.contributor.author | Selvarajah, D | |
dc.contributor.author | Kar, D | |
dc.contributor.author | Khunti, K | |
dc.contributor.author | Davies, MJ | |
dc.contributor.author | Scott, AR | |
dc.contributor.author | Walker, J | |
dc.contributor.author | Tesfaye, S | |
dc.date.accessioned | 2024-03-07T15:47:43Z | |
dc.date.available | 2024-03-07T15:47:43Z | |
dc.date.issued | 2019-12 | |
dc.identifier.issn | 2213-8587 | |
dc.identifier.issn | 2213-8595 | |
dc.identifier.uri | https://pearl.plymouth.ac.uk/handle/10026.1/22143 | |
dc.description.abstract |
Diabetic peripheral neuropathy (DPN) is a common complication of both type 1 and 2 diabetes. It is a leading cause of lower-limb amputation and disabling neuropathic pain. Amputations in patients with diabetes have a devastating effect on quality of life and are associated with an alarmingly low life expectancy (on average only 2 years from the amputation). Amputation also places a substantial financial burden on health-care systems and society in general. With the introduction of national diabetes eye screening programmes, the prevalence of blindness in working-age adults is falling. This is not the case, however, with diabetes related amputations. In this Review, we appraise innovative point-of-care devices that enable the early diagnosis of DPN and assess the evidence for early risk factor-based management strategies to reduce the incidence and slow the progression of DPN. We also propose a framework for screening and early multifactorial interventions as the best prospect for preventing or halting DPN and its devastating sequelae. | |
dc.format.extent | 938-948 | |
dc.format.medium | Print-Electronic | |
dc.language | en | |
dc.publisher | Elsevier BV | |
dc.subject | Diabetic Neuropathies | |
dc.subject | Humans | |
dc.subject | Mass Screening | |
dc.subject | Peripheral Nervous System Diseases | |
dc.subject | Time-to-Treatment | |
dc.title | Diabetic peripheral neuropathy: advances in diagnosis and strategies for screening and early intervention | |
dc.type | journal-article | |
dc.type | Review | |
plymouth.author-url | https://www.ncbi.nlm.nih.gov/pubmed/31624024 | |
plymouth.issue | 12 | |
plymouth.volume | 7 | |
plymouth.publisher-url | http://dx.doi.org/10.1016/s2213-8587(19)30081-6 | |
plymouth.publication-status | Published | |
plymouth.journal | The Lancet Diabetes & Endocrinology | |
dc.identifier.doi | 10.1016/s2213-8587(19)30081-6 | |
plymouth.organisational-group | |Plymouth | |
plymouth.organisational-group | |Plymouth|Faculty of Health | |
plymouth.organisational-group | |Plymouth|Users by role | |
plymouth.organisational-group | |Plymouth|Users by role|Academics | |
plymouth.organisational-group | |Plymouth|Faculty of Health|Peninsula Medical School | |
dc.publisher.place | England | |
dcterms.dateAccepted | 2019-01-03 | |
dc.date.updated | 2024-03-07T15:47:42Z | |
dc.identifier.eissn | 2213-8595 | |
dc.rights.embargoperiod | forever | |
rioxxterms.versionofrecord | 10.1016/s2213-8587(19)30081-6 |
Files in this item
Files | Size | Format | View |
---|---|---|---|
There are no files associated with this item. |